CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2023	Jan. 31, 2022	Jan. 31, 2021
Cash flows from operating activities:
Net loss	$ (797,526)	$ (679,948)	$ (539,102)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation and amortization	63,535	21,498	9,826
Non-cash operating lease costs	46,240	35,553	33,475
Amortization of deferred commissions	57,445	37,876	28,841
Stock-based compensation, net of amounts capitalized	861,533	605,095	301,441
Net amortization of premiums on investments	3,497	48,002	8,630
Net unrealized losses (gains) on strategic investments in equity securities	46,435	(27,621)	0
Deferred income tax	(26,664)	(717)	(30)
Other	1,618	2,014	4,610
Changes in operating assets and liabilities, net of effects of business combinations:
Accounts receivable	(166,965)	(251,652)	(116,289)
Deferred commissions	(95,107)	(95,877)	(51,444)
Prepaid expenses and other assets	(2,904)	(159,159)	(62,349)
Accounts payable	8,024	7,371	(2,878)
Accrued expenses and other liabilities	74,519	79,772	58,252
Operating lease liabilities	(42,342)	(38,249)	(31,281)
Deferred revenue	514,301	526,221	312,881
Net cash provided by (used in) operating activities	545,639	110,179	(45,417)
Cash flows from investing activities:
Purchases of property and equipment	(25,128)	(16,221)	(35,037)
Capitalized internal-use software development costs	(24,012)	(12,772)	(5,293)
Cash paid for business combinations, net of cash and cash equivalents acquired	(362,609)	0	(6,035)
Purchases of intangible assets	(700)	(24,334)	(8,374)
Purchases of investments	(3,901,321)	(4,250,338)	(4,859,852)
Sales of investments	58,813	440,069	177,070
Maturities and redemptions of investments	3,657,072	3,842,796	700,876
Net cash used in investing activities	(597,885)	(20,800)	(4,036,645)
Cash flows from financing activities:
Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs	0	0	478,573
Proceeds from initial public offering and private placements, net of underwriting discounts	0	0	4,242,284
Proceeds from early exercised stock options	0	0	159
Proceeds from exercise of stock options	39,893	127,036	53,378
Proceeds from issuance of common stock under employee stock purchase plan	40,931	52,227	0
Proceeds from repayments of a nonrecourse promissory note	0	0	2,090
Repurchases of early exercised stock options	0	0	(30)
Taxes paid related to net share settlement of equity awards	(184,648)	0	0
Capital contributions from noncontrolling interest holders	13,000	0	0
Payments of deferred purchase consideration for business combinations	(1,800)	(1,065)	(1,164)
Net cash provided by (used in) financing activities	(92,624)	178,198	4,775,290
Effect of exchange rate changes on cash, cash equivalents, and restricted cash	(933)	(236)	(11)
Net increase (decrease) in cash, cash equivalents, and restricted cash	(145,803)	267,341	693,217
Cash, cash equivalents, and restricted cash—beginning of period	1,102,534	835,193	141,976
Cash, cash equivalents, and restricted cash—end of period	956,731	1,102,534	835,193
Supplemental disclosures of cash flow information:
Cash paid for income taxes	6,550	1,482	1,195
Supplemental disclosures of non-cash investing and financing activities
Property and equipment included in accounts payable and accrued expenses	6,317	5,115	6,941
Stock-based compensation included in capitalized software development costs	28,467	23,620	2,072
Vesting of early exercised stock options	244	750	3,502
Issuance of common stock in connection with a business combination	438,916	0	0
Purchases of intangible assets included in accrued expenses and other liabilities	0	4,544	0
Reconciliation of cash, cash equivalents, and restricted cash:
Cash and cash equivalents	939,902	1,085,729	820,177
Restricted cash—included in other assets and prepaid expenses and other current assets	16,829	16,805	15,016
Total cash, cash equivalents, and restricted cash	$ 956,731	$ 1,102,534	$ 835,193